IL263657A - נוגדני אנטי-c5 ושיטות לשימושם - Google Patents
נוגדני אנטי-c5 ושיטות לשימושםInfo
- Publication number
- IL263657A IL263657A IL263657A IL26365718A IL263657A IL 263657 A IL263657 A IL 263657A IL 263657 A IL263657 A IL 263657A IL 26365718 A IL26365718 A IL 26365718A IL 263657 A IL263657 A IL 263657A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 | ||
| PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL263657A true IL263657A (he) | 2019-01-31 |
Family
ID=59969459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300611A IL300611A (he) | 2016-06-17 | 2017-06-16 | נוגדני אנטי–c5 ושיטות לשימושם |
| IL263657A IL263657A (he) | 2016-06-17 | 2018-12-12 | נוגדני אנטי-c5 ושיטות לשימושם |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300611A IL300611A (he) | 2016-06-17 | 2017-06-16 | נוגדני אנטי–c5 ושיטות לשימושם |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (he) |
| JP (3) | JP6202774B1 (he) |
| KR (2) | KR102226975B1 (he) |
| CN (3) | CN109312326B (he) |
| AU (1) | AU2017285763B2 (he) |
| BR (1) | BR112018075688A2 (he) |
| CA (1) | CA3021956A1 (he) |
| CL (1) | CL2018003573A1 (he) |
| CR (1) | CR20190013A (he) |
| EA (1) | EA201990018A1 (he) |
| IL (2) | IL300611A (he) |
| MX (2) | MX2018015030A (he) |
| MY (1) | MY187848A (he) |
| PE (1) | PE20190394A1 (he) |
| PH (1) | PH12018502354A1 (he) |
| SG (2) | SG10201800265UA (he) |
| TW (4) | TWI807666B (he) |
| UA (1) | UA126561C2 (he) |
| WO (1) | WO2017217524A1 (he) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
| EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| EP4238993A3 (en) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| SG11201607165YA (en) | 2014-12-19 | 2016-09-29 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| UA124734C2 (uk) | 2016-06-14 | 2021-11-10 | Рідженерон Фармасьютікалз, Інк. | Антитіло проти с5 і його застосування |
| AU2017285763B2 (en) * | 2016-06-17 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
| CA3078362A1 (en) * | 2017-10-04 | 2019-04-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| JP2021536509A (ja) * | 2018-09-06 | 2021-12-27 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒト化抗ｃ５抗体とその利用 |
| MX2021012997A (es) * | 2019-04-24 | 2022-03-04 | Univ Pennsylvania | Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos. |
| CN113563467A (zh) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | 针对人补体蛋白c5的抗体及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (he) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| JP4643139B2 (ja) | 2001-06-12 | 2011-03-02 | テレフオンアクチーボラゲット エル エム エリクソン（パブル） | Ｕｍｔｓ地上無線アクセスネットワーク（ｕｔｒａｎ）での同期 |
| JP4958387B2 (ja) | 2001-08-17 | 2012-06-20 | ジェネンテック， インコーポレイテッド | Ｃ５ｂの形成を妨害することなくｃ５及びｃ５ａに結合する補体経路阻害剤 |
| JP4333939B2 (ja) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | トロリ線の吊架装置 |
| DE10253331A1 (de) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Verwendung von trans-Pellitori als Aromastoff |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (ko) | 2007-03-20 | 2008-07-29 | (주)화도 | 폴리에틸렌 관 |
| EP2129681A2 (en) * | 2007-03-22 | 2009-12-09 | Novartis Ag | C5 antigens and uses thereof |
| JP5336846B2 (ja) | 2007-04-11 | 2013-11-06 | 積水化学工業株式会社 | 架橋ポリビニルアセタール樹脂の製造方法及び架橋ポリビニルアセタール樹脂 |
| EP4238993A3 (en) * | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| PL2328616T3 (pl) * | 2008-08-05 | 2015-10-30 | Novartis Ag | Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 |
| KR20100054403A (ko) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | 온라인 공동 작문 장치 및 방법 |
| CN102844332B (zh) * | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| KR20110111007A (ko) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Ｌ／ｄ 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체 |
| KR20110122011A (ko) | 2010-05-03 | 2011-11-09 | 황보철종 | 매장 포인트 통합 관리 시스템 및 그 방법 |
| NZ704771A (en) * | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| KR101638931B1 (ko) * | 2013-01-31 | 2016-07-12 | 서울대학교산학협력단 | 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법 |
| US20160051673A1 (en) * | 2013-03-29 | 2016-02-25 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| SG11201607165YA (en) * | 2014-12-19 | 2016-09-29 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| EP3390442B1 (en) * | 2015-12-18 | 2023-11-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
| AU2017285763B2 (en) * | 2016-06-17 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
-
2017
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/zh active Active
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/pt unknown
- 2017-06-16 TW TW111107923A patent/TWI807666B/zh active
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 TW TW112120479A patent/TW202337903A/zh unknown
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/ko active IP Right Grant
- 2017-06-16 TW TW106141573A patent/TWI789369B/zh active
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/es unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 IL IL300611A patent/IL300611A/he unknown
- 2017-06-16 EA EA201990018A patent/EA201990018A1/ru unknown
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/zh active Pending
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/es unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/zh active Pending
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/ko active IP Right Grant
- 2017-06-16 UA UAA201810992A patent/UA126561C2/uk unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/ja active Active
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 CR CR20190013A patent/CR20190013A/es unknown
- 2017-06-16 TW TW106120143A patent/TWI610941B/zh active
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/ja active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/es unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/es unknown
- 2018-12-12 IL IL263657A patent/IL263657A/he unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265800A (he) | נוגדנים אנטי-lag-3 ושיטות לשימוש בהם | |
| SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| RS64576B1 (sr) | Anti-tigit antitela i postupci njihove primene | |
| IL263657A (he) | נוגדני אנטי-c5 ושיטות לשימושם | |
| SG10201710322VA (en) | Anti-c5 antibodies and methods of use | |
| HK1251942A1 (zh) | 抗-c5抗體及使用方法 | |
| LT3601358T (lt) | Anti-trem2 antikūnai ir jų naudojimo metodai | |
| HK1259251A1 (zh) | 人源化抗c1s抗體及其使用方法 | |
| IL265957A (he) | נוגדנים אנטי c1s ושיטות לשימוש בהם | |
| IL274221A (he) | נוגדנים ל- anti-apoc3 ושיטות לשימוש | |
| ZA202002144B (en) | Antibodies and methods of use |